The effect of rifaximin on small intestinal motility and microbiota in patients with liver cirrhosis
Not Applicable
- Conditions
- iver cirrhosis
- Registration Number
- JPRN-UMIN000028986
- Lead Sponsor
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. The patient who is pregnant or performing breast feeding. 2. The patient who was registered in this study before. 3. The patient who has allergy to rifaximin. 4. The patient who has colostomy or cannot collect stool correctly. 5. The patient who has severe constipation and a risk for ileus by preparation for cine-MRI. 6. The patient who has contraindications for MRI (i.e. a cardiac pace maker, claustrophobia, metal product in the body, etc.). 7. The patients who are judged by the investigators to be inappropriate participants in the trial.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The changes of small intestinal motility before and after administration of rifaximin for 4 weeks.
- Secondary Outcome Measures
Name Time Method The changes of microbiota before and after administration of rifaximin for 4 weeks.